Ocuphire Pharma

Oral medications, like Ocuphire’s APX3330, hold promise in treating #retinaldiseases earlier in the disease process. Ocuphire CEO Dr. George Magrath will be discussing the need and opportunities associated with developing new oral therapies with differentiated mechanisms of action for #retinal diseases like #diabeticretinopathy during the Association for Research in Vision and Ophthalmology (ARVO) Special Interest Group (#ARVO SIG) panel, “Medications for the Management of Retinal Diseases,” tomorrow at 6 p.m. ET. More information on the panel ➡ https://lnkd.in/eYiM5mg6 #Ocuphire #ophthalmology

Thanks to the Retinal Imaging Biomarkers & Endpoints Summit for hosting a forum for leaders in the field to discuss the future of #retinaldisease research. Chief Scientific and Development Officer Dr. Ash Jayagopal highlighted Ocuphire’s insights in leveraging next-generation biomarker approaches to conduct efficient and high-quality clinical trials in #diabeticretinopathy, including:  ⚡ considerations for non-proliferative #diabeticretinopathy clinical trials;  ⚡ stratification and screening based on imaging biomarkers; ⚡ utility of ocular fluid biomarkers; and ⚡ next-gen vision testing options for retina. #Ocuphire #ophthalmology #retina #NPDR Image description: The image is the title slide of Dr. Jayagopal’s presentation, titled, “Multiplex analysis of clinical imaging and biomarker data for validating novel endpoints for Diabetic Retinopathy,” which includes the title, the name of the event, and the Ocuphire blue, orange and white logo.

Attending Hanson Wade Group’s #Retinal Imaging Biomarkers & Endpoints Summit meeting this week in Boston? Don’t miss Ocuphire’s Chief Scientific and Development Officer Dr. Ash Jayagopal discussing using clinical imaging and #biomarker data to validate novel endpoints for #diabeticretinopathy on Thursday, June 27th at 2 p.m. ET. More info ➡ https://lnkd.in/eWSgcjxm

This month, updates on the clinical program for our lead candidate APX3330 for #diabeticretinopathy will be featured at two #retinal meetings. Veeral Sheth, MD, MBA, FASRS, will deliver a clinical update presentation at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and Ocuphire’s Chief Scientific and Development Officer Dr. Ash Jayagopal will discuss using clinical imaging and biomarker data to validate novel endpoints for diabetic retinopathy at Hanson Wade Group’s Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston. Read the press release ➡ https://lnkd.in/e_ZxDN3x More information on CTS ➡ https://www.ctsretina.org/ More information on Retinal Imaging Biomarkers & Endpoints Summit ➡ https://lnkd.in/eWSgcjxm #Ocuphire #ophthalmology #retina Image description: The image shows a quote from George Magrath, M.D., Chief Executive Officer of Ocuphire Pharma. The quote states: “We are grateful for multiple opportunities to share an update on our APX3330 clinical program and our planned ZETA-2 pivotal trial, including the unmet need for an earlier intervention treatment to delay or prevent DR progression, the value of multimodal imaging in DR, and Phase 2/3 trial optimization and patient selection, with industry and scientific peers.”

This week, we’re at the BIO International Convention 2024 in San Diego. The Ocuphire team is looking forward to connecting with other innovators and leaders across the biotech industry and sharing more on our work addressing disease-related #visionloss. #BIO2024 

Members of our board and leadership team recently celebrated the opening of Ocuphire’s new laboratory space at BioLabs North Carolina in Durham, NC. This new space will expand our #research capabilities as we work toward deepening our understanding of the metabolic pathways that impact #retinalhealth to preserve the integrity of sight for more people. 

Please join Ocuphire's CEO, George Magrath, MD for the Retinal and Refractive Eye Disorder Webinar on Wednesday, May 15th.

Thanks Dr. Su for the great overview of the ZETA-1 trial (APX3330) and subset analysis.

If you’re headed to Retina World Congress 2024 in Fort Lauderdale, FL May 9-12, make sure to check out the e-Poster, APX3330: Developing an Oral, Small-Molecule Inhibitor of Ref-1 Therapy to Delay the Progression of Non-Proliferative Diabetic Retinopathy, presented by Rishi P. Singh, MD, FASRS (Cleveland Clinic Martin North and South Hospitals). #RWC2024 #RetinaWorldCongress #Ocuphire #ophthalmology # retina #diabeticretinopathy

Thank you Daniel Su, MD (Retina-Vitreous Associates Medical Group) for presenting Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale during the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle, WA. The paper presentation detailed results from the ZETA-1 Phase 2 subset analysis which represents the target population and the FDA-agreed upon registration endpoint for Ocuphire’s planned Phase 2/3 trial of APX3330. Learn more: https://lnkd.in/eJf4g-Md #ARVO2024 #Ocuphire #ophthalmology #optometry